Publicis Groupe SA (EPA:PUBP) confirmed its full-year growth guidance on Tuesday after first-quarter revenue rose 6.4% on an organic basis, even as a strengthening euro wiped €268 million from ... Nasdaq: Publicis Groupe SA (PUBGY) Upgraded to Buy: Here's What You Should Know Publicis Groupe SA (PUBGY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...
Publicis Groupe SA (PUBGY) Upgraded to Buy: Here's What You Should Know ABC7 San Francisco: Ad giant Publicis Health agrees to $350M settlement over claims it helped fuel opioid crisis PARIS -- A unit of French advertising giant Publicis Groupe SA agreed Thursday to pay $350 million to settle claims it helped OxyContin maker Purdue Pharma fuel the opioid epidemic in the United ... Ad giant Publicis Health agrees to $350M settlement over claims it helped fuel opioid crisis Publicis Groupe SA said it will invest €300 million ($327 million) in the next three years on artificial intelligence, including €100 million in 2024, as the new technology is increasingly used in the ... Forbes: Ad Agency Publicis Reaches First-Of-Its-Kind $350 Million Opioid Marketing Settlement, New York Attorney General Says New York Attorney General Letitia James announced Thursday that Publicis Health, one of the largest global health advertising agencies, will pay $350 million to settle allegations it “developed ... Ad Agency Publicis Reaches First-Of-Its-Kind $350 Million Opioid Marketing Settlement, New York Attorney General Says Yahoo: Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 million BOSTON (Reuters) -A division of French advertising company Publicis Groupe SA and drug company Hikma Pharmaceuticals have reached separate settlements worth a collective $500 million to resolve claims ...
publicis sa, Ad firm Publicis, drugmaker Hikma settle US opioid cases for $500 million Publicis Groupe SA (PUBGY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one ...
